Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry

Published:2019-03-28 Issue:1 Volume:48 Page:42-51
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Ge Zhen,Baber Usman,Claessen Bimmer E.,Chandrasekhar Jaya,Chandiramani Rishi,Li Shawn X.,Sartori Samantha,Kini Annapoorna S.,Rao Sunil V.,Weiss Sandra,Henry Timothy D.,Kapadia Samir,Muhlestein Brent,Strauss Craig,Toma Catalin,DeFranco Anthony,Effron Mark B.,Keller Stuart,Baker Brian A.,Pocock Stuart,Dangas George,Mehran Roxana

Funder

Eli Lily and Co.

Daiichi Sankyo Inc.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11239-019-01842-9.pdf

Reference21 articles.

1. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015

2. De Servi S, Goedicke J, Schirmer A, Widimsky P (2014) Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. Eur Heart J Acute Cardiovasc Care 3:363–372

3. Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723–731

4. Federspiel JJ, Anstrom KJ, Xian Y et al (2016) Comparing inverse probability of treatment weighting and instrumental variable methods for the evaluation of adenosine diphosphate receptor inhibitors after percutaneous coronary intervention. JAMA Cardiol 1:655–665

5. Zeymer U, Hochadel M, Lauer B et al (2015) Use, efficacy and safety of prasugrel in patients with ST segment elevation myocardial infarction scheduled for primary percutaneous coronary intervention in clinical practice. Results of the prospective ATACS-registry. Int J Cardiol 184:122–127

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes;Journal of Interventional Cardiology;2023-05-20

2. Prognostic role of the left ventricular global function index in predicting major adverse cardiovascular events in acute coronary syndrome patients;Biomarkers in Medicine;2023-03-21

3. Pharmacogenomics Informs Cardiovascular Pharmacotherapy;Methods in Molecular Biology;2022

4. One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration;Cardiovascular Drugs and Therapy;2021-01-30

5. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention;Alimentary Pharmacology & Therapeutics;2020-07-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3